Medigrowth backs National Pain Week 2026 as Gold Sponsor

Medigrowth has signed on as Gold Sponsor of National Pain Week 2026, joining Chronic Pain Australia’s July campaign to spotlight the experiences of Australians living with chronic pain. The partnership comes as new survey data shows growing use of medicinal cannabis among pain patients and continued concern about access barriers.

Why it matters: - National Pain Week is one of Australia’s main chronic pain awareness campaigns, and the Medigrowth partnership is aimed at reaching people who want clearer, evidence-based information about treatment options. - The campaign is focused on the 5.4 million Australians living with chronic pain. - Chronic Pain Australia wants the sponsorship to help reduce stigma, elevate lived experience and push for pain to be recognised as a National Health Priority Area.

What happened: - Medigrowth announced it will be Gold Sponsor of National Pain Week 2026, which runs from 26 to 31 July 2026. - Chronic Pain Australia and Medigrowth are partnering on patient-centred research, education and awareness activities. - Medigrowth also will be Gold Sponsor of the 2026 National Pain Report.

The details: - The partnership is built around a shared focus on balanced, evidence-based education and helping consumers make informed healthcare decisions with qualified health professionals. - Medigrowth created a five-part video series answering common questions about medicinal cannabis. - The videos are titled: “What’s the Deal with Medicinal Cannabis?”, “What Does Medicinal Cannabis Feel Like?”, “Will People Know I’ve Tried Medicinal Cannabis?”, “Will Medicinal Cannabis Work for Me?” and “Will Medicinal Cannabis Get Me High?” - Medigrowth also produced a longer interview called “Pain Lives in Women’s Health,” featuring Medigrowth’s Melanie Wentzel and Chronic Pain Australia General Manager Kellie Jade Ellis. - In the interview, the two discuss healthcare leadership and Ellis’s own endometriosis journey. - National Pain Week is built around the National Pain Survey, described as the longest-running survey of Australians living with chronic pain. - Chronic Pain Australia’s past three National Pain Reports show medicinal cannabis is playing a larger role in pain management. - In 2025, 31% of respondents had accessed medicinal cannabis for pain management, up from 28% in 2024. - Another 27.5% said they would like to or intend to try medicinal cannabis. - That means more than half of respondents either use medicinal cannabis or are interested in it as a treatment option. - The same reports show cost and driving restrictions have each eased slightly year over year as barriers. - Medigrowth describes itself as a biotechnology, digital health and clinical research organisation focused on cannabinoid therapeutics and evidence-based healthcare. - The company says its work includes clinical research, cannabinoid therapeutics for the Australian market and patient care through its digital health platform, Azure Health. - Medigrowth says its research spans women’s health, paediatric populations and chronic pain. - The company points to a randomised, double-blind, placebo-controlled trial with Deakin University and Swinburne University on CBD in children and families living with autism. - Medigrowth also points to the EMPOWER Project, a prospective, HREC-approved real-world evidence study following up to 5,000 patients over four years. - Chronic Pain Australia says it is the national voice for 3.6 million Australians living with chronic pain. - The non-profit says it was founded in 2001 and coordinates National Pain Week, the National Pain Survey, PainLink support services and a national network of peer-led Pain Support Groups. - More information is available in Medigrowth’s announcement and Chronic Pain Australia’s website.

Between the lines: - The sponsorship gives Medigrowth a platform inside a trusted patient advocacy campaign, which could help normalize discussion of medicinal cannabis in chronic pain care. - The survey numbers suggest medicinal cannabis is moving from a fringe option toward a more mainstream consideration among some pain patients. - The remaining barriers around cost and driving restrictions show that access and policy issues still shape treatment decisions.

What’s next: - National Pain Week will run from 26 to 31 July 2026. - Chronic Pain Australia will use the campaign and report release to keep attention on chronic pain care, stigma reduction and patient access. - Medigrowth’s videos and interview content are positioned to support the campaign’s outreach ahead of and during National Pain Week.

The bottom line: - Medigrowth is using National Pain Week 2026 to place medicinal cannabis squarely in Australia’s chronic pain conversation, while Chronic Pain Australia gains a sponsor with content and research to broaden the campaign’s reach.